These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

90 related articles for article (PubMed ID: 21856801)

  • 1. Clopidogrel hyporesponsiveness: are we all the same?
    Tan DS
    Am J Health Syst Pharm; 2011 Sep; 68(17):1578-80; author reply 1580. PubMed ID: 21856801
    [No Abstract]   [Full Text] [Related]  

  • 2. Clopidogrel hyporesponsiveness and the FDA boxed warning: detection and management of patients with genetic polymorphisms.
    Perry E
    Am J Health Syst Pharm; 2011 Mar; 68(6):529-32. PubMed ID: 21378302
    [No Abstract]   [Full Text] [Related]  

  • 3. Clopidogrel dosing based on genotype.
    Alexopoulos D; Xanthopoulou I
    JAMA; 2012 Mar; 307(10):1024; author reply 1024-5. PubMed ID: 22416093
    [No Abstract]   [Full Text] [Related]  

  • 4. Differential impacts of CYP2C19 gene polymorphisms on the antiplatelet effects of clopidogrel and ticlopidine.
    Maeda A; Ando H; Asai T; Ishiguro H; Umemoto N; Ohta M; Morishima M; Sumida A; Kobayashi T; Hosohata K; Ushijima K; Fujimura A
    Clin Pharmacol Ther; 2011 Feb; 89(2):229-33. PubMed ID: 21178986
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In brief: poor metabolizers of clopidogrel (plavix).
    Med Lett Drugs Ther; 2010 May; 52(1337):33. PubMed ID: 20431520
    [No Abstract]   [Full Text] [Related]  

  • 6. Clopidogrel, genetics, and drug responsiveness.
    Freedman JE; Hylek EM
    N Engl J Med; 2009 Jan; 360(4):411-3. PubMed ID: 19164193
    [No Abstract]   [Full Text] [Related]  

  • 7. The pharmacogenomics of clopidogrel.
    Levitt MR; Osbun JW; Kim LJ
    World Neurosurg; 2012; 77(3-4):406-7. PubMed ID: 22366366
    [No Abstract]   [Full Text] [Related]  

  • 8. [Informativeness of genetic factors for optimization of personalized therapy with clopidogrel].
    Knauér NIu; Lifshits GI; Voronina EN; Koleda NV; Gus'kova EV
    Kardiologiia; 2013; 53(8):72-5. PubMed ID: 24088005
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Clinical significance of interactions between clopidogrel and proton pump inhibitors].
    Kubica A; Koziński M; Grześk G; Goch A
    Kardiol Pol; 2011; 69(6):610-6. PubMed ID: 21678305
    [No Abstract]   [Full Text] [Related]  

  • 10. Pharmacogenomics and clopidogrel: irrational exuberance?
    Nissen SE
    JAMA; 2011 Dec; 306(24):2727-8. PubMed ID: 22203545
    [No Abstract]   [Full Text] [Related]  

  • 11. The genetic basis of platelet responsiveness to clopidogrel. A critical review of the literature.
    Fefer P; Matetzky S
    Thromb Haemost; 2011 Aug; 106(2):203-10. PubMed ID: 21792462
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clopidogrel poor metabolizers may need alternative to standard regimen.
    Thompson CA
    Am J Health Syst Pharm; 2010 May; 67(10):779-80. PubMed ID: 20479095
    [No Abstract]   [Full Text] [Related]  

  • 13. PPI interactions with clopidogrel revisited.
    Med Lett Drugs Ther; 2009 Feb; 51(1306):13-4. PubMed ID: 19229161
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cytochrome P-450 polymorphisms and response to clopidogrel.
    Miao J; Liu R; Li Z
    N Engl J Med; 2009 May; 360(21):2250-1. PubMed ID: 19469033
    [No Abstract]   [Full Text] [Related]  

  • 15. Unraveling the pharmacogenetics of clopidogrel: the paraoxonase-1 controversy.
    Snoep JD
    Circ Cardiovasc Interv; 2011 Oct; 4(5):401-4. PubMed ID: 22010185
    [No Abstract]   [Full Text] [Related]  

  • 16. [Genetic variability in the efficacy of clopidogrel].
    Kristensen KE; Rasmussen HB; Hansen PR
    Ugeskr Laeger; 2013 Mar; 175(11):729-32. PubMed ID: 23480885
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cytochrome P-450 polymorphisms and response to clopidogrel.
    Taubert D; Bouman HJ; van Werkum JW
    N Engl J Med; 2009 May; 360(21):2249-50; author reply 2251. PubMed ID: 19458375
    [No Abstract]   [Full Text] [Related]  

  • 18. Current status of clopidogrel pharmacogenomics.
    Giusti B; Gori AM; Marcucci R; Abbate R
    Pharmacogenomics; 2012 Nov; 13(15):1671-4. PubMed ID: 23171330
    [No Abstract]   [Full Text] [Related]  

  • 19. CYP2C19 genotype and outcomes of clopidogrel treatment.
    Siasos G; Tousoulis D; Stefanadis C
    N Engl J Med; 2011 Feb; 364(5):481-2. PubMed ID: 21288101
    [No Abstract]   [Full Text] [Related]  

  • 20. Inhibition of ADP-induced platelet aggregation by clopidogrel is related to CYP2C19 genetic polymorphisms.
    Chen BL; Zhang W; Li Q; Li YL; He YJ; Fan L; Wang LS; Liu ZQ; Zhou HH
    Clin Exp Pharmacol Physiol; 2008 Aug; 35(8):904-8. PubMed ID: 18346178
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.